Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant

뉴스 본문을 불러오고 있어요.

Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant | 웨이프 WAPE

Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant

기사 요약

관련 종목

댓글 —